Runt-related transcription factor 2 (RUNX2) is critical for the modulation of chondrocyte osteoblast differentiation and hypertrophy. Recently discovered RUNX2 somatic mutations, expressional signatures of RUNX2 in normal tissues and tumors, and the prognostic and clinical significance of RUNX2 in many types of cancer have attracted attention and led RUNX2 to be considered a biomarker for cancer. Many discoveries have illustrated the indirect and direct biological functions of RUNX2 in orchestrating cancer stemness, cancer metastasis, angiogenesis, proliferation, and chemoresistance to anticancer compounds, warranting further exploration of the associated mechanisms to support the development of a novel therapeutic strategy.
Symbol | Cancer Type | Prognosis | Endpoint | p Value | Case | Dataset | Method | Probe ID |
---|---|---|---|---|---|---|---|---|
RUNX2 | Glioma | Poor | Overall survival | 0.02 | 153 | TCGA | RNA Seq | |
RUNX2 | Thyroid Cancer | - | Overall survival | N.S. | 501 | TCGA | RNA Seq | |
RUNX2 | Lung Cancer | - | Overall survival | N.S. | 994 | TCGA | RNA Seq | |
RUNX2 | Colorectal Cancer | Poor | Overall survival | 0.04 | 597 | TCGA | RNA Seq | |
RUNX2 | Head and Neck Cancer | - | Overall survival | N.S. | 499 | TCGA | RNA Seq | |
RUNX2 | Stomach Cancer | Poor | Overall survival | <0.001 | 354 | TCGA | RNA Seq | |
RUNX2 | Liver Cancer | - | Overall survival | N.S. | 365 | TCGA | RNA Seq | |
RUNX2 | Pancreatic Cancer | Poor | Overall survival | 0.037 | 176 | TCGA | RNA Seq | |
RUNX2 | Renal Cancer | Poor | Overall survival | <0.001 | 877 | TCGA | RNA Seq | |
RUNX2 | Urothelial Cancer | Poor | Overall survival | <0.001 | 406 | TCGA | RNA Seq | |
RUNX2 | Prostate Cancer | - | Overall survival | N.S. | 494 | TCGA | RNA Seq | |
RUNX2 | Testis Cancer | - | Overall survival | N.S. | 134 | TCGA | RNA Seq | |
RUNX2 | Breast Cancer | - | Overall survival | N.S. | 1075 | TCGA | RNA Seq | |
RUNX2 | Cervical Cancer | Poor | Overall survival | 0.0089 | 291 | TCGA | RNA Seq | |
RUNX2 | Endometrial Cancer | - | Overall survival | N.S. | 541 | TCGA | RNA Seq | |
RUNX2 | Ovarian Cancer | - | Overall survival | N.S. | 373 | TCGA | RNA Seq | |
RUNX2 | Melanoma | - | Overall survival | N.S. | 102 | TCGA | RNA Seq | |
RUNX2 | Breast Cancer | Good | Relapse-free survival | <0.001 | 4929 | E-MTAB-365, E-TABM-43, GSE: 11,121, 12,093, | Array | 216994_s_at |
12,276, 1456, 16,391, 16,446, 16,716, 17,705, 17,907, | ||||||||
18,728, 19,615, 20,194, 20,271, 2034, 20,685, 20,711, | ||||||||
21,653, 22,093, 25,066, 2603, 26,971, 29,044, 2990, | ||||||||
31,448, 31,519, 32,646, 3494, 36,771, 37,946, 41,998, | ||||||||
42,568, 43,358, 43,365, 45,255, 4611, 46,184, 48,390, | ||||||||
50,948, 5327, 58,812, 61,304, 65,194, 6532, 69,031, | ||||||||
7390, 76,275, 78,958, 9195 | ||||||||
RUNX2 | Ovarian Cancer | Good | Progression-free survival | 0.0037 | 1435 | GSE: 14,764, 15,622, 18,520, 19,829, 23,554, 26,193, | Array | 216994_s_at |
26,712, 27,651, 30,161, 3149, 51,373, 63,885, 65,986, | RNA Seq | |||||||
9891, TCGA (N = 565) | ||||||||
RUNX2 | Lung Cancer | Poor | Postprogression survival | <0.001 | 1925 | CAARRAY, GSE: 14,814, 19,188, 29,013, 30,219, | Array | 216994_s_at |
31,210, 3141, 31,908, 37,745, 43,580, 4573, 50,081, | RNA Seq | |||||||
8894, TCGA (N = 133) | ||||||||
RUNX2 | Gastric Cancer | Poor | Postprogression survival | <0.001 | 875 | GSE: 14,210, 15,459, 22,377, 29,272, 51,105, 62,254 | Array | 216994_s_at |
This entry is adapted from the peer-reviewed paper 10.3390/ijms24087001